Under the agreement, Abzena will manufacture Magacizumab, an antibody created using the ‘Abzena inside’ Composite Human Antibody technology. Under earlier agreements with UCL, Abzena conducted the antibody humanization and
Savolitinib is a highly selective and potent oral c-Met inhibitor with global first-in-class potential. The first drug dose was administered on February 10, 2017. This Phase II study
Modus Therapeutics is currently recruiting patients in Europe, the Middle East and Caribbean in an ongoing Phase II clinical study with sevuparin for SCD. In the second half
The Offer was oversubscribed and comprises 48,309,179 New Ordinary Shares to be issued by the Company (prior to any exercise of the Over-Allotment Option) Total gross proceeds raised
The Pfizer facility is a key part of the supply chain for the Company’s Glatopa products. Pfizer has indicated that the warning letter does not restrict the production
SILIQ is indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have
Takeda president and CEO Christophe Weber said: “We are very pleased to have completed the acquisition of Ariad Pharmaceuticals. The addition of Ariad’s innovative targeted therapies and research
Versant seeded Jecure as part of the firm’s push to build on its past success in the fibrosis field, and was the sole investor in today’s $20m series
The multi-target expansion builds on the parties’ existing discovery and license partnership, entered into in December 2014, and was facilitated by Johnson & Johnson Innovation. This latest agreement
Headline results were announced in December 2016 and detailed study results are being presented at the annual Conference on Retroviruses and Opportunistic Infections in Seattle. Use of dolutegravir
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.